Intuitive Surgical (NASDAQ:ISRG) Stock Price Down 0.9% – Time to Sell?

Intuitive Surgical, Inc. (NASDAQ:ISRG) shares fell 0.9% during trading on Thursday . The stock traded as low as $597.77 and last traded at $603.30. 287,679 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 1,693,671 shares. The stock had previously closed at $608.48.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. increased their target price on Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Bernstein Bank raised their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. Erste Group Bank upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. CICC Research started coverage on shares of Intuitive Surgical in a report on Monday, January 27th. They issued a “neutral” rating and a $550.00 price target on the stock. Finally, Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $522.00 to $650.00 in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Stock Performance

The firm has a market cap of $215.03 billion, a PE ratio of 93.99, a price-to-earnings-growth ratio of 5.79 and a beta of 1.39. The stock has a 50-day simple moving average of $563.17 and a two-hundred day simple moving average of $522.88.

Insider Activity

In other news, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the completion of the sale, the chief financial officer now owns 2,630 shares of the company’s stock, valued at $1,502,019.30. This represents a 3.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Desantis sold 376 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,967,734. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,348 shares of company stock valued at $3,587,582 over the last three months. Insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Atala Financial Inc bought a new position in Intuitive Surgical in the 4th quarter worth $25,000. Hurley Capital LLC purchased a new stake in Intuitive Surgical in the 4th quarter worth approximately $28,000. Berbice Capital Management LLC purchased a new position in Intuitive Surgical during the fourth quarter valued at approximately $26,000. Parvin Asset Management LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $26,000. Finally, BankPlus Trust Department purchased a new position in shares of Intuitive Surgical during the 4th quarter valued at $28,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.